Science and Law
22nd February 2015

Using Proper Pharmacovigilance Techniques to Prevail in Drug and Device Cases

Dr. Steven Weisman, Ph.D. Head of Global Healthcare Products at Innovative Science Solutions (Morristown, NJ), will be speaking at the ABA’s 2015 Life Sciences Legal Summit being held on March 4, 2015 at Genentech in South San Francisco.

Using Proper Pharmacovigilance Techniques  to Prevail in Drug and Device Cases

Dr. Steven Weisman, Ph.D. Head of Global Healthcare Products at Innovative Science Solutions (Morristown, NJ), will be speaking at the ABA’s 2015 Life Sciences Legal Summit being held on March 4, 2015 at Genentech in South San Francisco.

Dr. Weisman, along with Donald F. (Fritz) Zimmer (King and Spaulding) and Krista L. Cosner, Senior Counsel, Medivation, Inc. will form a panel that will be informative to both in-house and outside counsel. The panel will be speaking about the evaluation of evidence for signal detection for pharmacovigilance purposes (and possible label revisions) and for causation assessments in courts of law.

This session will assist in-house counsel in advising pharmacovigilance and regulatory departments on the downstream legal significance of the description of evidence in various regulatory and company documents. The session will also assist outside counsel in obtaining a greater appreciation of the pharmacovigilance process within companies in meeting their regulatory obligations. The panel will also discuss how companies can proactively monitor the safety and effectiveness of their products to develop systems that can reduce liability claims.

To register, visit the ABA’s registration page here:

http://shop.americanbar.org/ebus/ABAEventsCalendar/EventDetails.aspx?productId=184622532

Additional Program Topics Include:

  • Regulatory Strategies for Life Science Companies
  • A View From The Bench: Managing Complex Litigation In California
  • Generic Drug Preemption and Innovator Liability Update
  • Managing The Corporate Counsel Relationship: Ingredients for a Successful Attorney-Client Relationship
  • Off Label Marketing In The Post Caronia World
  • Evaluating Evidence Used for Pharmacovigilance Signal Detection and Legal Causation Assessments
  • The Continued Viability of Brand Preemption Post-Levine
  • Negotiating an Effective Clinical Trial Agreement and Limiting Litigation Exposure
  • Emerging Intellectual Property Issues

Did you like this post? We are here to help! Schedule a consult with one of our experts.

Just fill out the form bellow and we will contact you with more information.

  • Hidden
  • This field is for validation purposes and should be left unchanged.

Recent Related Articles

Dr. David Schwartz’s IADC Presentation: The Use of Genetic Testing in the Courtroom [Download Slides]
15 July 2020
Dr. David Schwartz’s IADC Presentation: The Use of Genetic Testing in the Courtroom [Download Slides]

On Wednesday July 8, 2020, Dr. David Schwartz of Innovative Science Solutions presented at the IADC 2020 Virtual Annual Meeting on a panel titled The Use of Genetic Testing in the Courtroom. A complimentary copy of the panel presentation is now available for download. Read more

The Use of Genetic Testing in the Courtroom: Dr. David Schwartz will be Presenting at the IADC 2020 Virtual Annual Meeting
02 July 2020
The Use of Genetic Testing in the Courtroom: Dr. David Schwartz will be Presenting at the IADC 2020 Virtual Annual Meeting

Dr. David Schwartz of Innovative Science Solutions will be presenting at the IADC 2020 Virtual Annual Meeting on a panel titled The Use of Genetic Testing in the Courtroom. Read more

WEBINAR ANNOUNCEMENT: What’s in Those Genes?
12 June 2020
WEBINAR ANNOUNCEMENT: What’s in Those Genes?

Genetic Evidence Concerning Causation for Mesothelioma 16 June 2020 at 2pm Eastern Daylight Time. Read more

Talc and Asbestos Defendants Should Monitor and Utilize Published Studies Linking Mesothelioma to Genomic Causes
28 April 2020
Talc and Asbestos Defendants Should Monitor and Utilize Published Studies Linking Mesothelioma to Genomic Causes

Plaintiff experts having been asserting for decades that all mesotheliomas must be linked to some asbestos exposure. Indeed, this has led to the erroneous (but widespread) view that mesothelioma is a signature disease, only caused by asbestos exposure. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us